Axsome Therapeutics Inc. Surpasses Q2 2025 Expectations
Axsome Therapeutics, Inc., a biopharmaceutical company specializing in therapies for pain, neurological disorders, and central nervous system issues, has reported strong financial results for the second quarter of 2025. The company, which operates globally and is listed on the Nasdaq stock exchange, has seen its stock price rise following the announcement of its earnings.
On August 4, 2025, Axsome Therapeutics announced that its total net product revenue for the second quarter of 2025 reached $150.0 million. This represents a significant growth of 72% year-over-year and a 24% increase sequentially. The company’s flagship product, AUVELITY®, contributed $119.6 million in net product sales, marking an 84% year-over-year growth and a 24% sequential increase. Additionally, SUNOSI® generated $30.0 million in net product revenue, reflecting a 35% year-over-year growth and a 19% sequential increase.
The company’s earnings per share (EPS) for the quarter was -$0.97, which exceeded expectations by $0.15. Revenue also surpassed forecasts, coming in at $150.04 million, $12.02 million higher than anticipated. These results have positively impacted the company’s stock, which closed at $103.02 on July 31, 2025, up from its 52-week low of $75.56 on December 29, 2024.
Axsome Therapeutics’ market capitalization stands at $4.99 billion, with a price-to-earnings ratio of -17.57, reflecting the company’s current financial performance and growth trajectory. The company’s pipeline remains on track, with the recent launch of SYMBRAVO® on June 10, 2025, adding to its portfolio of innovative therapies.
Analysts have taken note of Axsome Therapeutics’ strong performance in Q2 2025, with the company’s stock gaining momentum as a result. The company’s ability to exceed revenue and earnings expectations highlights its potential for continued growth in the competitive pharmaceutical sector.
As Axsome Therapeutics continues to expand its product offerings and advance its pipeline, investors and stakeholders will be closely monitoring its progress in addressing unmet medical needs in pain management and neurological disorders. For more information on Axsome Therapeutics’ operations and offerings, visit their website at www.axsome.com .